NACI Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)

The Medicago COVID-19 vaccine (Covifenz) is the first virus-like particle (VLP) COVID-19 vaccine authorized in Canada. Medicago Covifenz was authorized for use in adults 18-64 years of age by Health Canada on February 24, 2022. The National Advisory Committee on Immunization’s (NACI) recommendations are aligned with the following goals of the Canadian COVID-19 Immunization Program, updated in October 2021:

• To enable as many Canadians as possible to be immunized as quickly as possible against COVID-19, while ensuring that high risk populations be prioritized;
• To minimize serious illness and overall deaths while preserving health system capacity;
• To reduce transmission to protect high risk populations.

Refer to the chapter on COVID-19 vaccine in the Canadian Immunization Guide for further information on COVID-19 vaccines.